Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide

Tatsuaki Iwama, Kazutaka Horie, Toshiaki Yoshikawa, Daisuke Nobuoka, Manami Shimomura, Yu Sawada, Tetsuya Nakatsura

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Glypican-3 (GPC3) is overexpressed in human hepatocellular carcinoma (HCC) but not expressed in normal tissues except for placenta and fetal liver and therefore is an ideal target for cancer immunotherapy. In this study, we identified an H2-Kb or H2-Db restricted and murine GPC3 (mGPC3)-derived cytotoxic T-lymphocyte (CTL) epitope peptide in C57BL/6 (B6) mice, which can be used in the design of preclinical studies of various therapies with GPC3-target immunotherapy in vivo. First, 11 types of 9- to 10-mer peptides predicted to bind with H2-Kb or H2-Db were selected from the mGPC3 amino acid sequence based on the binding score as calculated by the BIMAS software. We evaluated the peptide-binding affinity and confirmed that all peptides were able to bind to H2-Kb or H2-D b by in vitro cellular binding assay. Subsequently, a mixed peptide vaccine and single peptide vaccine were given to B6 mice to evaluate immunogenic potential of the 11 selected peptides. Using the splenocytes from peptide-vaccinated mice, interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assays showed that mGPC3-1127-136 (AMFKNNYPSL) peptide was the most efficient for inducing CTLs among the 11 peptides. Next, we demonstrated that the mGPC3-1 peptide-specific CTL line could recognize mGPC3-expressing cancer cells, suggesting that mGPC3-1 peptide was an endogenously presented peptide. In conclusion, we identified mGPC3-1 as an H2-Kb or H2-Db restricted, mGPC3-derived CTL epitope peptide.

Original languageEnglish
Pages (from-to)831-838
Number of pages8
JournalInternational Journal of Oncology
Volume42
Issue number3
DOIs
Publication statusPublished - Mar 2013
Externally publishedYes

Fingerprint

Glypicans
T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Peptides
Subunit Vaccines
Immunotherapy
Enzyme-Linked Immunospot Assay
Interferons
Placenta

Keywords

  • Cytotoxic T-lymphocyte epitope
  • Glypican-3
  • Hepatocellular carcinoma
  • Mouse

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Iwama, T., Horie, K., Yoshikawa, T., Nobuoka, D., Shimomura, M., Sawada, Y., & Nakatsura, T. (2013). Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. International Journal of Oncology, 42(3), 831-838. https://doi.org/10.3892/ijo.2013.1793

Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. / Iwama, Tatsuaki; Horie, Kazutaka; Yoshikawa, Toshiaki; Nobuoka, Daisuke; Shimomura, Manami; Sawada, Yu; Nakatsura, Tetsuya.

In: International Journal of Oncology, Vol. 42, No. 3, 03.2013, p. 831-838.

Research output: Contribution to journalArticle

Iwama, T, Horie, K, Yoshikawa, T, Nobuoka, D, Shimomura, M, Sawada, Y & Nakatsura, T 2013, 'Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide', International Journal of Oncology, vol. 42, no. 3, pp. 831-838. https://doi.org/10.3892/ijo.2013.1793
Iwama, Tatsuaki ; Horie, Kazutaka ; Yoshikawa, Toshiaki ; Nobuoka, Daisuke ; Shimomura, Manami ; Sawada, Yu ; Nakatsura, Tetsuya. / Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. In: International Journal of Oncology. 2013 ; Vol. 42, No. 3. pp. 831-838.
@article{7114e3b18da44e97b6e29d597f0a8d46,
title = "Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide",
abstract = "Glypican-3 (GPC3) is overexpressed in human hepatocellular carcinoma (HCC) but not expressed in normal tissues except for placenta and fetal liver and therefore is an ideal target for cancer immunotherapy. In this study, we identified an H2-Kb or H2-Db restricted and murine GPC3 (mGPC3)-derived cytotoxic T-lymphocyte (CTL) epitope peptide in C57BL/6 (B6) mice, which can be used in the design of preclinical studies of various therapies with GPC3-target immunotherapy in vivo. First, 11 types of 9- to 10-mer peptides predicted to bind with H2-Kb or H2-Db were selected from the mGPC3 amino acid sequence based on the binding score as calculated by the BIMAS software. We evaluated the peptide-binding affinity and confirmed that all peptides were able to bind to H2-Kb or H2-D b by in vitro cellular binding assay. Subsequently, a mixed peptide vaccine and single peptide vaccine were given to B6 mice to evaluate immunogenic potential of the 11 selected peptides. Using the splenocytes from peptide-vaccinated mice, interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assays showed that mGPC3-1127-136 (AMFKNNYPSL) peptide was the most efficient for inducing CTLs among the 11 peptides. Next, we demonstrated that the mGPC3-1 peptide-specific CTL line could recognize mGPC3-expressing cancer cells, suggesting that mGPC3-1 peptide was an endogenously presented peptide. In conclusion, we identified mGPC3-1 as an H2-Kb or H2-Db restricted, mGPC3-derived CTL epitope peptide.",
keywords = "Cytotoxic T-lymphocyte epitope, Glypican-3, Hepatocellular carcinoma, Mouse",
author = "Tatsuaki Iwama and Kazutaka Horie and Toshiaki Yoshikawa and Daisuke Nobuoka and Manami Shimomura and Yu Sawada and Tetsuya Nakatsura",
year = "2013",
month = "3",
doi = "10.3892/ijo.2013.1793",
language = "English",
volume = "42",
pages = "831--838",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide

AU - Iwama, Tatsuaki

AU - Horie, Kazutaka

AU - Yoshikawa, Toshiaki

AU - Nobuoka, Daisuke

AU - Shimomura, Manami

AU - Sawada, Yu

AU - Nakatsura, Tetsuya

PY - 2013/3

Y1 - 2013/3

N2 - Glypican-3 (GPC3) is overexpressed in human hepatocellular carcinoma (HCC) but not expressed in normal tissues except for placenta and fetal liver and therefore is an ideal target for cancer immunotherapy. In this study, we identified an H2-Kb or H2-Db restricted and murine GPC3 (mGPC3)-derived cytotoxic T-lymphocyte (CTL) epitope peptide in C57BL/6 (B6) mice, which can be used in the design of preclinical studies of various therapies with GPC3-target immunotherapy in vivo. First, 11 types of 9- to 10-mer peptides predicted to bind with H2-Kb or H2-Db were selected from the mGPC3 amino acid sequence based on the binding score as calculated by the BIMAS software. We evaluated the peptide-binding affinity and confirmed that all peptides were able to bind to H2-Kb or H2-D b by in vitro cellular binding assay. Subsequently, a mixed peptide vaccine and single peptide vaccine were given to B6 mice to evaluate immunogenic potential of the 11 selected peptides. Using the splenocytes from peptide-vaccinated mice, interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assays showed that mGPC3-1127-136 (AMFKNNYPSL) peptide was the most efficient for inducing CTLs among the 11 peptides. Next, we demonstrated that the mGPC3-1 peptide-specific CTL line could recognize mGPC3-expressing cancer cells, suggesting that mGPC3-1 peptide was an endogenously presented peptide. In conclusion, we identified mGPC3-1 as an H2-Kb or H2-Db restricted, mGPC3-derived CTL epitope peptide.

AB - Glypican-3 (GPC3) is overexpressed in human hepatocellular carcinoma (HCC) but not expressed in normal tissues except for placenta and fetal liver and therefore is an ideal target for cancer immunotherapy. In this study, we identified an H2-Kb or H2-Db restricted and murine GPC3 (mGPC3)-derived cytotoxic T-lymphocyte (CTL) epitope peptide in C57BL/6 (B6) mice, which can be used in the design of preclinical studies of various therapies with GPC3-target immunotherapy in vivo. First, 11 types of 9- to 10-mer peptides predicted to bind with H2-Kb or H2-Db were selected from the mGPC3 amino acid sequence based on the binding score as calculated by the BIMAS software. We evaluated the peptide-binding affinity and confirmed that all peptides were able to bind to H2-Kb or H2-D b by in vitro cellular binding assay. Subsequently, a mixed peptide vaccine and single peptide vaccine were given to B6 mice to evaluate immunogenic potential of the 11 selected peptides. Using the splenocytes from peptide-vaccinated mice, interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assays showed that mGPC3-1127-136 (AMFKNNYPSL) peptide was the most efficient for inducing CTLs among the 11 peptides. Next, we demonstrated that the mGPC3-1 peptide-specific CTL line could recognize mGPC3-expressing cancer cells, suggesting that mGPC3-1 peptide was an endogenously presented peptide. In conclusion, we identified mGPC3-1 as an H2-Kb or H2-Db restricted, mGPC3-derived CTL epitope peptide.

KW - Cytotoxic T-lymphocyte epitope

KW - Glypican-3

KW - Hepatocellular carcinoma

KW - Mouse

UR - http://www.scopus.com/inward/record.url?scp=84873666983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873666983&partnerID=8YFLogxK

U2 - 10.3892/ijo.2013.1793

DO - 10.3892/ijo.2013.1793

M3 - Article

C2 - 23354275

AN - SCOPUS:84873666983

VL - 42

SP - 831

EP - 838

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -